# Vaxcyte, Inc.: overview

PCVX · Nasdaq · CIK 1649094 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pcvx.md) · [Financials](/companies/pcvx/financials.md) · [Filings](/companies/pcvx/filings.md) · [Insiders](/companies/pcvx/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.83)](/filings/0001649094-25-000114.md) | not reported | [(1.04)](/filings/0001649094-26-000017.md) | [(1.22)](/filings/0001649094-26-000043.md) | [(1.56)](/filings/0001649094-25-000114.md) | not reported | [(2.30)](/filings/0001649094-26-000017.md) | [(1.97)](/filings/0001649094-26-000043.md) |
| Free cash flow | $m | [(65.7) d](/filings/0001649094-25-000114.md) | [(115) d](/filings/0001649094-26-000007.md) | [(172)](/filings/0001649094-26-000017.md) | [(123) d](/filings/0001649094-26-000043.md) | [(147) d](/filings/0001649094-25-000114.md) | [(227) d](/filings/0001649094-26-000007.md) | [(283)](/filings/0001649094-26-000017.md) | [(237) d](/filings/0001649094-26-000043.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.93)](/filings/0000950170-24-021145.md) | [(3.44)](/filings/0001649094-25-000028.md) | [(4.14)](/filings/0001649094-26-000007.md) | [(3.80)](/filings/0001649094-26-000007.md) | [(5.63)](/filings/0001649094-26-000007.md) |
| Free cash flow | $m | [(128)](/filings/0000950170-24-021145.md) | [(176)](/filings/0001649094-25-000028.md) | [(313)](/filings/0001649094-26-000007.md) | [(475)](/filings/0001649094-26-000007.md) | [(669)](/filings/0001649094-26-000007.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pcvx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.21bn | 20,852,907 |  | Added +4,360,046 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $1.04bn | 17,965,847 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $960.2m | 16,575,875 |  | Not compared |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $701.5m | 12,068,129 |  | Added +1,096,313 |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $667.0m | 11,474,599 |  | Unchanged |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $407.0m | 7,001,565 |  | Added +1,386,968 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $383.3m | 6,593,551 |  | Added +314,006 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $369.0m | 6,348,679 |  | Added +81,978 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $311.1m | 5,351,698 |  | Added +911,179 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $250.0m | 4,300,000 |  | Unchanged |

## Recent filings

[All 760 filings](/companies/pcvx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-09 | 20:42 ET | [8-K](/filings/0001193125-26-419174.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-419174 |
| 2026-10-05 | 12:01 ET | [8-K](/filings/0001193125-26-413168.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-413168 |
| 2026-09-03 | 20:18 ET | [8-K](/filings/0001649094-26-000045.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001649094-26-000045 |
| 2026-08-05 | 20:13 ET | [10-Q](/filings/0001649094-26-000043.md) | Quarterly report, period 2026-06-30 | 0001649094-26-000043 |
| 2026-08-05 | 20:07 ET | [8-K](/filings/0001649094-26-000041.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-26-000041 |
| 2026-07-15 | 20:05 ET | [8-K](/filings/0001649094-26-000030.md) | 5.02 Departure or appointment of officers or directors | 0001649094-26-000030 |
| 2026-06-23 | 20:09 ET | [8-K](/filings/0001649094-26-000026.md) | 5.02 Departure or appointment of officers or directors | 0001649094-26-000026 |
| 2026-06-16 | 20:12 ET | [8-K](/filings/0001649094-26-000021.md) | 5.07 Shareholder vote results | 0001649094-26-000021 |
| 2026-05-06 | 20:12 ET | [10-Q](/filings/0001649094-26-000017.md) | Quarterly report, period 2026-03-31 | 0001649094-26-000017 |
| 2026-05-06 | 20:08 ET | [8-K](/filings/0001649094-26-000015.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001649094-26-000015 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001649094-26-000007.md), filed Feb 24, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1649094
- Tickers: PCVX
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.